摘要
目的观察甲磺酸阿帕替尼片治疗晚期非小细胞肺癌的临床效果。方法选取2020年7月-2021年7月在我院诊治的48例晚期非小细胞肺癌患者为研究对象,采用随机数字表法分为对照组和观察组,各24例。对照组采用常规化疗,观察组在对照组基础上给予甲磺酸阿帕替尼片治疗。比较两组治疗总有效率、肿瘤标记物水平[癌胚抗原(CEA)、细胞角蛋白19片段(CYFRA21-1)、血管内皮生长因子(VEGF)]、卡氏健康评分、中位生存时间及不良反应发生率。结果观察组治疗总有效率为91.67%,高于对照组的83.33%(P<0.05);两组CEA、CYFRA21-1、VEGF水平均低于治疗前,且观察组低于对照组(P<0.05);两组卡氏健康评分均高于治疗前,且观察组高于对照组(P<0.05);观察组中位生存时间长于对照组(P<0.05);观察组不良反应发生率为16.67%,低于对照组的29.16%(P<0.05)。结论甲磺酸阿帕替尼片治疗晚期非小细胞肺癌效果确切,可减少肿瘤标志物的表达、提高卡氏健康评分、延长患者中位生存时间、降低不良反应发生率,是一种安全、有效的治疗药物。
Objective To observe the clinical effect of apatinib mesylate tablets in the treatment of advanced non-small cell lung cancer.Methods A total of 48 patients with advanced non-small cell lung cancer diagnosed and treated in our hospital from July 2020 to July 2021 were selected as the research objects.They were divided into control group and observation group by random number table method,with 24 cases in each group.The control group was treated with conventional chemotherapy,and the observation group was treated with apatinib mesylate tablets on the basis of the control group.The total effective rate,tumor marker levels[carcinoembryonic antigen(CEA),cytokeratin 19 fragment(CYFRA21-1),vascular endothelial growth factor(VEGF)],Karnofsky health score,median survival time and incidence of adverse reactions were compared between the two groups.Results The total effective rate of treatment in the observation group was 91.67%,which was higher than 83.33%in the control group(P<0.05).The levels of CEA,CYFRA21-1 and VEGF in the two groups were lower than those before treatment,and the observation group was lower than the control group(P<0.05).The KPS scores of the two groups were higher than those before treatment,and the observation group was higher than the control group(P<0.05).The median survival time of the observation group was longer than that of the control group(P<0.05).The incidence of adverse reactions in the observation group was 16.67%,which was lower than 29.16%in the control group(P<0.05).Conclusion Apatinib mesylate tablets are effective in the treatment of advanced non-small cell lung cancer,which can reduce the expression of tumor markers,improve the Karnofsky health score,prolong the median survival time of patients,reduce the incidence of adverse reactions.It is a safe and effective treatment drug.
作者
石少庆
SHI Shao-qing(The Fifth Department of Oncology,Jiamusi Tumor Tuberculosis Hospital,Jiamusi 154007,Heilongjiang,China)
出处
《医学信息》
2023年第1期152-154,共3页
Journal of Medical Information
关键词
甲磺酸阿帕替尼片
晚期非小细胞肺癌
癌胚抗原
细胞角蛋白19片段
Apatinib Mesylate tablets
Advanced non-small cell lung cancer
Carcinoembryonic antigen
Cytokeratin 19 fragment
